Basic Information
| LncRNA/CircRNA Name | RP11-135L22.1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | ovarian cancer |
| ICD-0-3 | C56.9 |
| Methods | qRT-PCR, Western blot |
| Sample | ovarian cancer tissues, ovarian cancer cell lines (A2780, HEY, HO8910) |
| Expression Pattern | down-regulated |
| Function Description | RP11-135L22.1 was lowly expressed in ovarian cancer.RP11-135L22.1 expression was negatively correlated with the treating time and dose of cisplatin. Western blot showed that cisplatin induced autophagy in ovarian cancer cells in a time- and dose-dependent manner. Cisplatin combined with RP11-135L22.1 can reduce autophagy, increase the apoptosis and inhibit its activity of ovarian cancer cells to a certain extent. |
| Pubmed ID | 29509240 |
| Year | 2018 |
| Title | Cisplatin suppresses tumor proliferation by inhibiting autophagy in ovarian cancer via long non-coding RNA RP11-135L22.1. |
External Links
| Links for RP11-135L22.1 | GenBank HGNC NONCODE |
| Links for ovarian cancer | OMIM COSMIC |